Peer-influenced content. Sources you trust. No registration required. This is HCN.

Practical NeurologyFDA Gives Fast Track Designation for Basimglurant in Individuals with Trigeminal Neuralgia

Basimglurant is a highly selective, potent, and cell-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5). Based on the LibraTN trial — a 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study of basimglurant for trigeminal neuralgia, FDA has granted the molecule Fast Track designation.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form